Comparative safety and effectiveness of cholinesterase inhibitors and memantine for Alzheimer's disease: a network meta-analysis of 41 randomized controlled trials.

ABSTRACT:

Background

Cholinesterase inhibitors and memantine have been approved for management of Alzheimer's disease (AD), but there has been no consensus about the choice of various types and doses of drugs at different stages. Hence, we compared and ranked the efficacy and tolerability of these available drugs.

Methods

We searched PubMed, the Cochrane Central Register of Controlled Trials, and Embase for randomized controlled trials (RCTs) published from database inception to July 21, 2017. The primary outcomes were the mean overall changes in cognitive function and responders who had any adverse events. We conducted a random-effects network meta-analysis.

Results

Forty-one RCTs were included in this study. Compared with placebo, galantamine 32 mg daily (standardized mean di

SUBMITTER: Dou KX 

PROVIDER: S-EPMC6309083 | biostudies-literature | 2018 Dec

REPOSITORIES: biostudies-literature